Dataset

62 residual BALF specimens with culture results (Hu et al. 2026)

Residual bronchoalveolar lavage fluid specimens with traceable culture results, sequenced by both clinical workflows.

Evaluation results

6 evaluations · 108 results. Different protocols are not a single leaderboard.

Filter evaluations

Tested model or methodProtocolDatasetEvaluation setupMetricEvidence origin

Applied filters: All linked evaluations

Source checking is not independent reproduction. Release 2026-10-22-1b7cf027e4f6.

Research readiness

0 of 4 readiness checks met. These checks assess whether the evidence supports a reproducible investigation; a source-checked score alone does not meet them.

Readiness checks, gaps and artifacts

Release 2026-10-22-1b7cf027e4f6 · Evidence verified: Not verified

Evidence incomplete

Replay metrics

Exact outcomes, predictions, identifiers and evaluator are connected.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
File checksums match the recorded files: not yet verified
Predictions are matched to the right samples: not yet verified
Score meaning and direction are confirmed: not yet verified
Metrics are recomputed from the saved predictions: not yet verified

Verified: Not verified

Evidence incomplete

Investigate discrepancies

Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
File checksums match the recorded files: not yet verified
Predictions are matched to the right samples: not yet verified
Score meaning and direction are confirmed: not yet verified
Metrics are recomputed from the saved predictions: not yet verified
Sample annotations are recorded: not yet verified
Dependence between samples is assessed: not yet verified

Verified: Not verified

Evidence incomplete

Run locally

A pinned recipe describes the inputs, environment and resource requirements.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
File checksums match the recorded files: not yet verified
Predictions are matched to the right samples: not yet verified
Score meaning and direction are confirmed: not yet verified
A pinned run recipe exists: not yet verified
Compute requirements are estimated: not yet verified

Verified: Not verified

Evidence incomplete

Validate independently

Separate data and exposure records support an independent test.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
File checksums match the recorded files: not yet verified
Predictions are matched to the right samples: not yet verified
Score meaning and direction are confirmed: not yet verified
Independent validation data exist: not yet verified
Overlap with training data is checked: not yet verified

Verified: Not verified

Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.

Artifacts and reproduction

No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.

Dataset and evaluation context

A dataset supplies biological observations. The evaluation protocol defines how those observations are split, used and scored.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

8 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-10-22-1b7cf027e4f6
Property and statement	Original source and location	Review and provenance
Access Not stated in the inspected text Context-only references	Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy Original source ↗ Methods 'Clinical performance evaluation and reference standards' paragraph 1; Results 'Diagnostic performance for clinical samples' paragraph 1; Discussion limitations paragraph Version: Microbiology Spectrum 14(7):e03993-25, published 2026-06-03; PMC13339908 full-text XML Retrieved: 2026-10-11T21:37:24Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.access` Source artifact SHA-256: `555995fd870d878dd0e6c112064bbf1d2535a1cb1af17f70570ecc11774caa2d` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Denominator 62 Context-only references	Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy Original source ↗ Methods 'Clinical performance evaluation and reference standards' paragraph 1; Results 'Diagnostic performance for clinical samples' paragraph 1; Discussion limitations paragraph Version: Microbiology Spectrum 14(7):e03993-25, published 2026-06-03; PMC13339908 full-text XML Retrieved: 2026-10-11T21:37:24Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.denominator` Source artifact SHA-256: `555995fd870d878dd0e6c112064bbf1d2535a1cb1af17f70570ecc11774caa2d` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Population 62 BALF specimens, primarily from lower respiratory tract infection; per workflow, Table 2 counts 77 organism results against culture, 96 against CMT and 133 against CRS Context-only references	Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy Original source ↗ Methods 'Clinical performance evaluation and reference standards' paragraph 1; Results 'Diagnostic performance for clinical samples' paragraph 1; Discussion limitations paragraph Version: Microbiology Spectrum 14(7):e03993-25, published 2026-06-03; PMC13339908 full-text XML Retrieved: 2026-10-11T21:37:24Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.population` Source artifact SHA-256: `555995fd870d878dd0e6c112064bbf1d2535a1cb1af17f70570ecc11774caa2d` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Source location Methods 'Clinical performance evaluation and reference standards' paragraph 1; Results 'Diagnostic performance for clinical samples' paragraph 1; Discussion limitations paragraph Context-only references	Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy Original source ↗ Methods 'Clinical performance evaluation and reference standards' paragraph 1; Results 'Diagnostic performance for clinical samples' paragraph 1; Discussion limitations paragraph Version: Microbiology Spectrum 14(7):e03993-25, published 2026-06-03; PMC13339908 full-text XML Retrieved: 2026-10-11T21:37:24Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.source_locator` Source artifact SHA-256: `555995fd870d878dd0e6c112064bbf1d2535a1cb1af17f70570ecc11774caa2d` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Split Single clinical set; no split Context-only references	Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy Original source ↗ Methods 'Clinical performance evaluation and reference standards' paragraph 1; Results 'Diagnostic performance for clinical samples' paragraph 1; Discussion limitations paragraph Version: Microbiology Spectrum 14(7):e03993-25, published 2026-06-03; PMC13339908 full-text XML Retrieved: 2026-10-11T21:37:24Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.split` Source artifact SHA-256: `555995fd870d878dd0e6c112064bbf1d2535a1cb1af17f70570ecc11774caa2d` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Version As described in Hu et al. 2026 Context-only references	Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy Original source ↗ Methods 'Clinical performance evaluation and reference standards' paragraph 1; Results 'Diagnostic performance for clinical samples' paragraph 1; Discussion limitations paragraph Version: Microbiology Spectrum 14(7):e03993-25, published 2026-06-03; PMC13339908 full-text XML Retrieved: 2026-10-11T21:37:24Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.version` Source artifact SHA-256: `555995fd870d878dd0e6c112064bbf1d2535a1cb1af17f70570ecc11774caa2d` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Description Residual bronchoalveolar lavage fluid specimens with traceable culture results, sequenced by both clinical workflows. Context-only references	Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy Original source ↗ Methods 'Clinical performance evaluation and reference standards' paragraph 1; Results 'Diagnostic performance for clinical samples' paragraph 1; Discussion limitations paragraph Version: Microbiology Spectrum 14(7):e03993-25, published 2026-06-03; PMC13339908 full-text XML Retrieved: 2026-10-11T21:37:24Z	not individually reviewed No individual claim review recorded Audit details Field: `description` Source artifact SHA-256: `555995fd870d878dd0e6c112064bbf1d2535a1cb1af17f70570ecc11774caa2d` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
Name 62 residual BALF specimens with culture results (Hu et al. 2026) Context-only references	Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy Original source ↗ Methods 'Clinical performance evaluation and reference standards' paragraph 1; Results 'Diagnostic performance for clinical samples' paragraph 1; Discussion limitations paragraph Version: Microbiology Spectrum 14(7):e03993-25, published 2026-06-03; PMC13339908 full-text XML Retrieved: 2026-10-11T21:37:24Z	not individually reviewed No individual claim review recorded Audit details Field: `name` Source artifact SHA-256: `555995fd870d878dd0e6c112064bbf1d2535a1cb1af17f70570ecc11774caa2d` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact

How to read the evidence

Sources and history

Release 2026-10-22-1b7cf027e4f6 · Record review: source checked

1 source record and release history

Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Original source · Microbiology Spectrum 14(7):e03993-25, published 2026-06-03; PMC13339908 full-text XML

Download this release (gzip)

Technical metadata and extraction receipts

Stable ID: dna-pathogen-20261011-hu2026-data-balf62

areas: microbes-communities
contexts: clinical_research
version: As described in Hu et al. 2026
population: 62 BALF specimens, primarily from lower respiratory tract infection; per workflow, Table 2 counts 77 organism results against culture, 96 against CMT and 133 against CRS
split: Single clinical set; no split
denominator: 62
access: Not stated in the inspected text
source locator: Methods 'Clinical performance evaluation and reference standards' paragraph 1; Results 'Diagnostic performance for clinical samples' paragraph 1; Discussion limitations paragraph

Related records

Suggest a correction

Exact evaluated configurations and original reported results
Tested configuration	Protocol and dataset	Finding	Evidence and details
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	7 False negatives (sequencing negative, comparator positive; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) count · lower Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "TGS", column group "Clinical microbiological tests (CMT)", row "−" (sequencing negative), column "＋" (comparator positive)
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	10 False positives (sequencing positive, comparator negative; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) count · lower Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "TGS", column group "Clinical microbiological tests (CMT)", row "＋" (sequencing positive), column "−" (comparator negative)
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	79.2% Specificity (negative percent agreement; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "TGS", column group "Clinical microbiological tests (CMT)", row "NPA"
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	84.1% Recall (positive percent agreement; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "TGS", column group "Clinical microbiological tests (CMT)", row "PPA"
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	42 True negatives (concordant negative; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) count · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "TGS", column group "Clinical microbiological tests (CMT)", row "−" (sequencing negative), column "−" (comparator negative)
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	37 True positives (concordant positive; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) count · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "TGS", column group "Clinical microbiological tests (CMT)", row "＋" (sequencing positive), column "＋" (comparator positive)
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	4 False negatives (sequencing negative, comparator positive; organism level; organisms: bacteria; reference: clinical microbiological tests (CMT)) count · lower Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 6, block "TGS", column group "Clinical microbiological tests (CMT)", row "−" (sequencing negative), column "＋" (comparator positive)
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	5 False positives (sequencing positive, comparator negative; organism level; organisms: bacteria; reference: clinical microbiological tests (CMT)) count · lower Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 6, block "TGS", column group "Clinical microbiological tests (CMT)", row "＋" (sequencing positive), column "−" (comparator negative)
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	88.9% Specificity (negative percent agreement; organism level; organisms: bacteria; reference: clinical microbiological tests (CMT)) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 6, block "TGS", column group "Clinical microbiological tests (CMT)", row "NPA"
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	86.2% Recall (positive percent agreement; organism level; organisms: bacteria; reference: clinical microbiological tests (CMT)) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 6, block "TGS", column group "Clinical microbiological tests (CMT)", row "PPA"
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	40 True negatives (concordant negative; organism level; organisms: bacteria; reference: clinical microbiological tests (CMT)) count · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 6, block "TGS", column group "Clinical microbiological tests (CMT)", row "−" (sequencing negative), column "−" (comparator negative)
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	25 True positives (concordant positive; organism level; organisms: bacteria; reference: clinical microbiological tests (CMT)) count · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 6, block "TGS", column group "Clinical microbiological tests (CMT)", row "＋" (sequencing positive), column "＋" (comparator positive)
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	3 False negatives (sequencing negative, comparator positive; organism level; organisms: fungi; reference: clinical microbiological tests (CMT)) count · lower Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 7, block "TGS", column group "Clinical microbiological tests (CMT)", row "−" (sequencing negative), column "＋" (comparator positive)
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	5 False positives (sequencing positive, comparator negative; organism level; organisms: fungi; reference: clinical microbiological tests (CMT)) count · lower Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 7, block "TGS", column group "Clinical microbiological tests (CMT)", row "＋" (sequencing positive), column "−" (comparator negative)
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	91.2% Specificity (negative percent agreement; organism level; organisms: fungi; reference: clinical microbiological tests (CMT)) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 7, block "TGS", column group "Clinical microbiological tests (CMT)", row "NPA"
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	76.9% Recall (positive percent agreement; organism level; organisms: fungi; reference: clinical microbiological tests (CMT)) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 7, block "TGS", column group "Clinical microbiological tests (CMT)", row "PPA"
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	52 True negatives (concordant negative; organism level; organisms: fungi; reference: clinical microbiological tests (CMT)) count · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 7, block "TGS", column group "Clinical microbiological tests (CMT)", row "−" (sequencing negative), column "−" (comparator negative)
Configuration: Host-depleted ONT GridION mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	10 True positives (concordant positive; organism level; organisms: fungi; reference: clinical microbiological tests (CMT)) count · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Host-depleted ONT GridION mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 7, block "TGS", column group "Clinical microbiological tests (CMT)", row "＋" (sequencing positive), column "＋" (comparator positive)
Configuration: MGISEQ-200 short-read mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	5 False negatives (sequencing negative, comparator positive; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) count · lower Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source MGISEQ-200 short-read mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "NGS", column group "Clinical microbiological tests (CMT)", row "−" (sequencing negative), column "＋" (comparator positive)
Configuration: MGISEQ-200 short-read mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	13 False positives (sequencing positive, comparator negative; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) count · lower Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source MGISEQ-200 short-read mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "NGS", column group "Clinical microbiological tests (CMT)", row "＋" (sequencing positive), column "−" (comparator negative)
Configuration: MGISEQ-200 short-read mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	75% Specificity (negative percent agreement; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source MGISEQ-200 short-read mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "NGS", column group "Clinical microbiological tests (CMT)", row "NPA"
Configuration: MGISEQ-200 short-read mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	88.6% Recall (positive percent agreement; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source MGISEQ-200 short-read mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "NGS", column group "Clinical microbiological tests (CMT)", row "PPA"
Configuration: MGISEQ-200 short-read mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	39 True negatives (concordant negative; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) count · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source MGISEQ-200 short-read mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "NGS", column group "Clinical microbiological tests (CMT)", row "−" (sequencing negative), column "−" (comparator negative)
Configuration: MGISEQ-200 short-read mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	39 True positives (concordant positive; organism level; organisms: all organisms; reference: clinical microbiological tests (CMT)) count · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source MGISEQ-200 short-read mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Benchmarking next- versus third-generation sequencing in metagenomics: performance metrics and diagnostic efficacy · Table 2, block "NGS", column group "Clinical microbiological tests (CMT)", row "＋" (sequencing positive), column "＋" (comparator positive)
Configuration: MGISEQ-200 short-read mNGS workflow (Hu et al. 2026)	Protocol: Organism-level agreement with clinical microbiological tests (CMT), 62 BALF specimens (Hu et al. 2026) Dataset: 62 residual BALF specimens with culture results (Hu et al. 2026)	3 False negatives (sequencing negative, comparator positive; organism level; organisms: bacteria; reference: clinical microbiological tests (CMT)) count · lower Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source MGISEQ-200 short-read mNGS workflow (Hu et al. 2026) against clinical microbiological tests (CMT) dna-pathogen-20261011-hu2026-protocol-cmt Aggregation: Not reported Hu et al. 2026 Supplemental Tables S1 to S4, S6 and S7 (spectrum.03993-25-s0001.docx) · Supplemental Table 6, block "NGS", column group "Clinical microbiological tests (CMT)", row "−" (sequencing negative), column "＋" (comparator positive)